1355. Systems Biology of Vaccination for AS03-adjuvanted H5N1 Avian Influenza in Humans
Session: Oral Abstract Session: Vaccines for Seasonal and Avian Flu: Who Knew?
Saturday, October 10, 2015: 9:45 AM
Room: 5--AB


The molecular mechanisms by which adjuvants enhance immune responses to pandemic influenza vaccines are poorly understood. We evaluated transcriptomic responses in human immune cells to H5N1 vaccine administered with or without Adjuvant System 03 (AS03).


Healthy subjects aged 18-49 years received two 3.75 mcg doses of subvirion inactivated influenza A/H5N1 virus vaccine with either AS03 (n=10) or saline (PBS; n=10). Blood samples were obtained on Days -28, -14, 0 (pre-vaccination), 1, 3, 7, and 28 relative to first vaccination for transcriptomic profiling of six immune cell types: neutrophils, B and T lymphocytes, monocytes, dendritic cells (DC), and natural killer cells (NK). 25 million, 50 BP, paired-end sequencing was performed on RNA from each cell type at each time point. Differentially-expressed (DE) genes between treatment groups were identified, with p-value adjustment for multiple comparisons. Genes with a false-discovery rate value 0.05 and fold change of ³1.5 (up or down) between treatments were considered DE.


Most variation was driven by cell type, with distinct clusters for lymphocytes/NK, DC/monocytes, and neutrophils (Figure 1). Monocytes, DC, and neutrophils showed many DE genes at Day 1 post-vaccination with 80 DE genes shared by all three cell types. B and T lymphocytes exhibited increased responses at Day 1 as well, albeit with fewer DE genes. With the exception of neutrophils at Day 3, few genes had significant differences in log fold-changes between treatments at Day 3, 7, or 28. NK demonstrated a distinct pattern with weak responses at Day 1 and moderate responses at Days 3 and 28. At Day 1, subjects tended to cluster by treatment group based on log­ fold changes of DE genes at any post-vaccination day  (Figure 2). Except for NK, subject clustering by treatment became weaker over time, indicating that the effect of adjuvant on gene expression responses rapidly declined.


Transcriptional profiling of immune cells after vaccination reveals distinct signatures in the early immune response to AS03-adjuvanted compared to non-adjuvanted vaccine. Application of this approach may offer new insights into the mechanisms of immune responses to influenza vaccines and oil-in-water adjuvants.

* Howard, Hoek, and Goll contributed equally to this work.

Leigh Howard, MD, MPH1, Kristen Hoek, PhD2, Johannes Goll, M.S.3, Parimal Samir, M.Tech.4, Allison Galassie, B.S.5, C. Buddy Creech, MD, MPH, FPIDS6, Nripesh Prasad, PhD7, Travis Jensen, B.S.8, Heather Hill, MS9, Sebastian Joyce, PhD10, Kathryn Edwards, MD, FIDSA1 and Andrew Link, PhD2, (1)Pediatrics, Vanderbilt University Medical Center, Nashville, TN, (2)Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, (3)The EMMES Corporation, Rockville, MD, (4)Biochemistry, Vanderbilt University Medical Center, Nashville, TN, (5)Chemistry, Vanderbilt University Medical Center, Nashville, TN, (6)Vanderbilt Vaccine Research Program and Division of Pediatric Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN, (7)HudsonAlpha Institute for Biotechnology, Huntsville, AL, (8)The EMMES Corporation, Rockeville, MD, (9)EMMES Corporation, Rockville, MD, (10)Vanderbilt University, nashville, TN


L. Howard, None

K. Hoek, None

J. Goll, None

P. Samir, None

A. Galassie, None

C. B. Creech, None

N. Prasad, None

T. Jensen, None

H. Hill, None

S. Joyce, None

K. Edwards, None

A. Link, None

<< Previous Abstract | Next Abstract

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.